Arcutis Biotherapeutics beat analysts’ expectations in the first quarter with a smaller net loss than expected and a secure financial runway for its next few years of drug development. Arcutis, a pre-revenue biotechnology company in Westlake Village focused on treating skin diseases, had a net loss of $64.3 million, or $1.27 per share, in the…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
